港股午後跌幅曾扩至逾200点再寻底腾讯/舜宇/中资保险及药股领跌
美国制造业PMI疲弱，拖累摩通5月全球制造业PMI重陷收缩报49.8创逾六年半低，加上贸易战升级，市场忧虑环球经济衰退。澳洲央行今天议息结果如期近三年首次减息，是继新西兰後第二个发达国家减息。沪深股市午後沽盘重现，上证及深成续跌1.1%及1.4%分别报2,858及8,733。
港股五连跌，恒指今早在中移动(00941.HK)及友邦(01299.HK)高开逾1%支撑，高开100点或0.4%报26,994欠承接，掉头向下，午後跌幅曾扩至221点，低见26,671屡创逾四个月低，现造26,708，续跌184点或近0.7%，但成交额仅602亿元。
蓝筹股普遍下跌，金融股以中国平安(02318.HK)及国寿(02628.HK)表现最差，股价双双失守10天线，报84.35元及17.68元，挫2.5%及2.8%。此外，重磅股腾讯(00700.HK)及舜宇(02382.HK)跌1.9%及2.2%，分别报327.2元及67.2元，齐失守10天线。
内需股旺旺(00151.HK)及吉利(00175.HK)跌逾2%分别报5.65元及12.5元，股价齐失10天线。相反，恒安(01044.HK)及万洲(00288.HK)反覆逆升1.5%及1.9%，分别报58.75元及6.99元。
创科(00669.HK)跌2%报49.5元，股价失守10天线。此外，金沙(01928.HK)创五个月低，最低见32.8元，现造33.2元，续挫3.2%。
国家财政部联同医保局成立工作组稽查77家药企会计信息真实性，蓝筹石药(01093.HK)及中生制药(01177.HK)续跌4.3%及2.2%，分别报12.02及7.64元，前者股价创四个半月低。三生制药(01530.HK)也续跌3.7%报12.14元屡创近期新低。康希诺生物(06185.HK)创上市新低，最低见29.3元，现造29.95元，续挫6.1%。
太古A(00019.HK)反覆续升1.5%报94.45元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
